ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Up 9.3% in June

ABIVAX Société Anonyme (NASDAQ:ABVX) saw a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 107,900 shares, an increase of 9.3% from the May 31st total of 98,700 shares. Based on an average trading volume of 52,600 shares, the short-interest ratio is currently 2.1 days. Approximately 0.2% of the company’s stock are sold short.

Hedge Funds Weigh In On ABIVAX Société Anonyme

A number of hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets purchased a new stake in shares of ABIVAX Société Anonyme during the 1st quarter valued at about $81,000. Capstone Investment Advisors LLC bought a new position in ABIVAX Société Anonyme during the fourth quarter valued at approximately $618,000. Ghisallo Capital Management LLC purchased a new stake in ABIVAX Société Anonyme in the fourth quarter worth approximately $642,000. Kennedy Capital Management LLC grew its position in ABIVAX Société Anonyme by 35.3% in the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock worth $1,718,000 after purchasing an additional 31,331 shares during the period. Finally, Rosalind Advisors Inc. purchased a new stake in ABIVAX Société Anonyme during the 1st quarter valued at $5,411,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Trading Down 3.2 %

ABVX stock opened at $13.07 on Thursday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 4.08 and a current ratio of 4.08. ABIVAX Société Anonyme has a 1-year low of $7.99 and a 1-year high of $17.02. The business has a fifty day moving average price of $13.96 and a 200-day moving average price of $13.37.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Morgan Stanley boosted their price target on ABIVAX Société Anonyme from $15.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 11th. BTIG Research initiated coverage on ABIVAX Société Anonyme in a report on Monday, May 20th. They issued a “buy” rating and a $43.00 target price on the stock. Guggenheim began coverage on ABIVAX Société Anonyme in a report on Monday, April 29th. They set a “buy” rating and a $50.00 price target for the company. Finally, Piper Sandler began coverage on shares of ABIVAX Société Anonyme in a research note on Monday, April 29th. They issued an “overweight” rating and a $42.00 price target on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $34.20.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.